Cardiovascular Systems Inc CSII
We take great care to ensure that the data presented and summarized in this overview for Cardiovascular Systems Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CSII
View allLatest Institutional Activity in CSII
Top Purchases
Top Sells
About CSII
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Insider Transactions at CSII
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 27
2023
|
Scott R. Ward Chairman and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
811,022
-85.65%
|
$16,220,440
$20.0 P/Share
|
|
Apr 27
2023
|
Alexander Rosenstein General Counsel & Corp. Sec. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
148,673
-86.22%
|
$2,973,460
$20.0 P/Share
|
|
Apr 27
2023
|
William E. Cohn Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,449
-100.0%
|
$188,980
$20.0 P/Share
|
|
Apr 27
2023
|
Stephen Stenbeck Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,153
-100.0%
|
$63,060
$20.0 P/Share
|
|
Apr 27
2023
|
Augustine Lawlor Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
25,318
-100.0%
|
$506,360
$20.0 P/Share
|
|
Apr 27
2023
|
Augustine Lawlor Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,022
-100.0%
|
$100,440
$20.0 P/Share
|
|
Apr 27
2023
|
Martha Goldberg Aronson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,411
-100.0%
|
$248,220
$20.0 P/Share
|
|
Apr 27
2023
|
Sandra Sedo Chief Compliance Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
114,384
-85.79%
|
$2,287,680
$20.0 P/Share
|
|
Apr 27
2023
|
Stephen J. Rempe Chief Human Resources Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
84,220
-94.92%
|
$1,684,400
$20.0 P/Share
|
|
Apr 27
2023
|
Jeffrey S. Points Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
173,008
-90.16%
|
$3,460,160
$20.0 P/Share
|
|
Apr 27
2023
|
Erik Paulsen Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
700
-100.0%
|
$14,000
$20.0 P/Share
|
|
Feb 13
2023
|
Sandra Sedo Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,077
+4.25%
|
-
|
|
Feb 13
2023
|
Scott R. Ward Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,077
+0.62%
|
-
|
|
Feb 13
2023
|
Stephen J. Rempe Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,077
+5.69%
|
-
|
|
Feb 13
2023
|
Alexander Rosenstein General Counsel & Corp. Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
5,077
+3.3%
|
-
|
|
Feb 13
2023
|
Jeffrey S. Points Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,077
+2.85%
|
-
|
|
Feb 12
2023
|
Sandra Sedo Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
984
-0.89%
|
$18,696
$19.7 P/Share
|
|
Feb 12
2023
|
Scott R. Ward Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,493
-0.18%
|
$28,367
$19.7 P/Share
|
|
Feb 12
2023
|
Stephen J. Rempe Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
984
-1.24%
|
$18,696
$19.7 P/Share
|
|
Feb 12
2023
|
Alexander Rosenstein General Counsel & Corp. Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
984
-0.68%
|
$18,696
$19.7 P/Share
|